Digital X-ray Market outlook with industry review and forecasts

The growth of the market is attributed to the increasing geriatric population and subsequent growth in global disease incidence, favorable regulations and government initiatives & investments, the advantages of digital X-ray systems, and technological advancements and product development.

The Digital X-ray Market is expected to reach USD 13.04 billion by 2023 from USD 8.68 billion in 2018, at a CAGR of 8.5%.

Download PDF Brochure :- 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1164                                         

Based on application, the digital X-ray market is segmented into general radiography, dental applications, fluoroscopy, and mammography. In 2018, the general radiography segment is expected to account for the largest share of the digital X-ray market. The growth in this market is mainly driven by the rising prevalence of diseases like tuberculosis, osteoporosis, and CVD; growing aging population; and product launches.

By technology, the digital X-ray market is segmented into direct radiography and computed radiography. The direct radiography segment is expected to register the highest rate during the forecast period. The advantages associated with the use of direct radiography systems, such as effective dynamic range, better contrast detectability, better medical evaluation, superior and more accurate images, reduced radiation exposure for patients and workers, flexibility in image management, improved patient throughput, superior evaluation of data and images, and lower operational costs, are promoting the growth of the direct radiography segment in the digital X-ray market.

In 2018, North America is expected to dominate the market. The large share of this geographical segment is attributed to factors such strong economies in the US and Canada, which have allowed for significant investments in new technologies. Europe is expected to hold the second-largest share of this market. 

Read More :- https://www.marketsandmarkets.com/PressReleases/digital-x-ray.asp

The digital X-ray market is highly competitive with the presence of several small and big players. Some of the players in the digital X-ray market are Canon Inc. (Japan), Carestream Health (US), Fujifilm Corporation (Japan), GE Healthcare (US), Hitachi Ltd. (Japan), Hologic, Inc. (US), Philips Healthcare (Netherlands), Shimadzu Corporation (Japan), Siemens Healthineers (Germany), Konica Minolta, Inc. (Japan), Samsung Medison Co., Ltd. (Korea), and Agfa Gevaert (Belgium).

Blood Screening Market : An Outlook to the Future Global Opportunities

The increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens are the key factors driving the growth of this market.

The Blood Screening Market is projected to reach USD 3.3 billion by 2024 from USD 2.2 billion in 2019, at a CAGR of 8.7%.

Download PDF Brochure :- 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267747042

Based on product & service, the blood screening market is segmented into reagents and kits, instruments, and software and services. 

The reagents and kits segment accounted for the largest share of the blood screening market in 2018. The large share of this segment can be attributed to the high consumption and repeated use of reagents & kits in blood screening procedures. Also, the accessibility of a wide range of reagents and the need for reliable, specific, and fast detection of TTIs are driving the growth of the blood screening reagents & kits market.

Based on end users, the blood screening market is segmented into blood banks and hospitals. The blood bank segment accounted for the larger market share in 2018 and is projected to witness a higher growth rate during the forecast period. This can be attributed to the increasing demand for donated blood, a growing number of organ transplantation surgeries, rising awareness regarding the safety of blood, an increasing number of donations worldwide, and growth in government funding to charitable trusts.

Based on region, the blood screening market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. In 2018, North America accounted for the largest market share, followed by Europe. 

Read More :- 

https://www.marketsandmarkets.com/PressReleases/blood-screening.asp

The prominent players operating in the blood screening market include Grifols (Spain), F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), BioMérieux (France), Bio-Rad Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US) ,Ortho Clinical Diagnostics, Inc.(US), Becton, Dickinson and Company (US), DiaSorin (Italy), GFE (Germany), Trinity Biotech (Ireland), Merck Millipore (Germany), GE Healthcare (US), Perkin Elmer (US), Bio-Techne Corporation (US), and J Mitra & Co. Pvt. Ltd (India).

Gastrointestinal Stent Market : An Outlook to the Future Global Opportunities

The increasing preference for minimally invasive surgeries and rising prevalence of GI cancers and other digestive diseases are the major factors driving the growth of the gastrointestinal stent market. The base year considered for the study is 2016, while, the forecast period is 2017 to 2022.

The global Gastrointestinal Stent Market is projected to reach USD 452.6 Million by 2022 from USD 353.4 Million in 2017, at a CAGR of 5.1% during the forecast period. 

Download PDF Brochure :-

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=167758126

On the basis of disease type, the biliary diseases segment accounted for the largest share of the gastrointestinal stent market. The large share of this segment is attributed to the high prevalence of gastrointestinal diseases in the elderly population.

On the basis of product, the biliary stent segment accounted for the largest share of the global gastrointestinal stent market. This can be attributed to the high prevalence of pancreatic cancer and biliary diseases as well as growth in the number of surgical procedures for the treatment of these diseases.

Based on end user, the ambulatory surgery centers segment is expected to register the highest CAGR during the forecast period. Scheduling delays for operation, slow operating room turnover times, and the need for increasing the number of operating rooms in hospitals are the major factors supporting the growth of ASCs.

North America accounted for the largest share of the gastrointestinal stent market in 2016, followed by Europe and Asia Pacific. 

Read More :- 

https://www.marketsandmarkets.com/PressReleases/gastrointestinal-gi-stent.asp

The prominent players in the global gastrointestinal stent market are Boston Scientific (US), Cook Group (US), C.R. Bard (US), ELLA-CS (Czech Republic), Becton, Dickinson and Company (US), Merit Medical Systems (US), CONMED (US), Cantel Medical (US), Olympus (Japan), Taewoong Medical (South Korea), Micro-Tech (Nanjing) (China), Endo-Flex (Germany), and M.I. Tech (South Korea).

Urinary Catheters Market - Global Forecast to 2022

The growth in this market is mainly driven by the growing prevalence of urinary incontinence, increasing number of surgical procedures across the globe, and the favorable reimbursement scenario. The growing preference for single-use catheters and self-catheterization is a major trend that is expected to boost market growth in the coming years.

The Urinary Catheters Market is expected to reach USD 2.19 Billion by 2022 from USD 1.45 Billion in 2017, at a CAGR of 8.5% during the forecast period. 

Download PDF Brochure :- 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132934629

Based on product, the urinary catheters market is segmented into Foley catheters, intermittent catheters, and condom catheters. In 2017, the Foley catheters segment is expected to dominate this market, primarily due to the rising geriatric population and increasing incidence of urinary incontinence.

On the basis of type, the urinary catheters market is segmented into coated urinary catheters and uncoated urinary catheters. In 2017, coated urinary catheters are expected to dominate the market. Coated catheters ensure easier, more comfortable insertion, thereby reducing the risk of urethral damage and leading to better patient satisfaction. These advantages are driving the adoption of coated catheters.

On the basis of the region, the urinary catheters market is segmented into North America, Europe, Asia, and RoW. In 2017, North America accounted for the largest share of the market, followed by Europe, The large share of this regional segment can primarily be attributed to the increasing number of surgical procedures, rising prevalence of urinary incontinence, and presence of major players in the North American region. Asia is projected to register the highest growth rate during the forecast period.

Read More :- 

https://www.marketsandmarkets.com/PressReleases/urinary-catheter.asp

The urinary catheters market is highly competitive with the presence of major players. B. Braun Melsungen AG (Germany), Coloplast A/S (Denmark), C.R. Bard, Inc. (US), Hollister Incorporated (US), Medtronic plc (Ireland), Cook Medical (US), Teleflex Incorporation (US), and ConvaTec Group plc (UK) are the major companies operating in the urinary catheters market.

Preimplantation Genetic Testing Market Segments by Countries, Types, Applications and Top Key Players

Factors such as the growing rate of infertility across the globe, increasing public-private investments in the field of preimplantation genetic testing, rising number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and high risk of chromosomal abnormalities in the fetus with increasing maternal age are driving the growth of this market.

The global Preimplantation Genetic Testing Market is projected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%.

Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605

By type, the preimplantation genetic screening segment accounted for the largest share of the market. The large share of this segment can primarily be attributed to the decrease in female fertility (due to rising maternal age), increasing prevalence of genetic disorders in offspring, and benefits of PGS, such as increased chances of healthy pregnancy across all age groups, better implantation rate, reduced risks of miscarriage, reduced IVF cycle time, and comprehensive analysis of all 24 chromosome types.

The aneuploidy segment is expected to grow at the fastest CAGR. Growth of this segment can be attributed to the increasing maternal age, rising incidence of aneuploidy disorders, and strategic initiatives by key players to provide technologically advanced PGS products for aneuploidy screening. Aneuploidy screening has been reported to increase the chance of successful embryo implantation, decreases miscarriage rate, and reduce the chance of having a child with a chromosome abnormality).

Geographically, the preimplantation genetic testing market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest share of the market in 2016, followed by Europe. 

Read more :- https://www.marketsandmarkets.com/PressReleases/preimplantation-genetic-testing.asp

As of 2016, the major product manufacturers operating in the global market included Illumina, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), and SciGene Corporation (U.S.), among others. 

CT Scanner Market Set for Rapid Growth and Trend by 2022

The report analyzes and studies the major drivers, restraints, opportunities, and challenges of the CT scanners market in North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Factors like growing need for effective and early diagnosis, rising global prevalence of targeted, increasing preference for minimally invasive diagnostic procedures, increasing benefits of CT scans, and technological advancements are driving the growth of the market.              

The Global CT Scanner Market is projected to reach USD 6.20 Billion by 2022, at a CAGR of 5.4% during the forecast period.

Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=184364345

On the basis of technology, the CT scanners market is segmented into high-slice CT, mid-slice CT, low-slice CT, and cone beam CT technology. The cone beam CT technology segment is expected to grow faster than the other segments during the forecast period, majorly due to factors like procedural advantages; rising market demand for cosmetic dentistry; and ongoing product development & commercialization across major healthcare markets.

Based on type, the CT scanners market is divided into stationary and portable CT scanners. Portable CT scanners segment is poised to grow faster than the other segment due to increasing number of device installations across major markets, growing application horizons, and the lower switching costs provided by portable CT scanners.

Geographically, the CT scanner market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest share of the market in 2017.

Speak To Analyst :- https://www.marketsandmarkets.com/PressReleases/ct-scanner.asp

The major players in the CT scanner market are Koninklijke Philips N.V. (Netherlands), GE Healthcare (U.S.), Toshiba Corporation (Japan), Siemens AG (Germany), Hitachi Ltd. (Japan), Shimadzu Corporation (Japan), Samsung Electronics Co., Ltd. (South Korea), Neusoft Medical Systems Co., Ltd. (China), Medtronic plc (Ireland), Shenzhen Anke High-tech Co., Ltd. (Hong Kong), Accuray Incorporated (U.S.), PlanMED (Finland), Koning Corporation (U.S.), Carestream Health Inc. (U.S.), and PointNix Co. Ltd (South Korea).

Needles Market to Witness Steady Growth in the Near Future

Factors like the increasing number of blood donations and technological advancements in blood collection sets are driving the growth of the blood collection needles market.

The report studies the global Needles Market over the forecast period of 2017 to 2022. The market is expected to reach USD 8.47 Billion by 2022, at CAGR of 7.8% during the forecast period. 

Download PDF Brochure:-

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=223979930            

On the basis of type, the global needles market is segmented into two broad categories, namely, conventional needles and safety needles. 

The conventional needles market is estimated to command the larger share of the global needles market in 2017. The growing demand for biosimilar products, the increasing incidence of chronic disease, and the expanding injectables market are the key factors contributing to the growth of this market segment.

Based on product, the market is segmented into suture needles, blood collection needles, ophthalmic needles, dental needles, insufflation needles, pen needles, and other needles. While the pen needles segment is expected to hold the largest share of the in 2017, it is the blood collection needles segment that is expected to grow at a significant CAGR from 2017 to 2022. 

The needles market is segmented into hypodermic, intravenous, intramuscular, and intraperitoneal needles on the basis of delivery mode. The hypodermic needles segment is expected to account for the largest share of the needles market in 2017. 

As of 2016, North America held the largest share of the global needles market, followed by Europe. Its dominant share is attributed to the rising incidence of chronic diseases, initiatives by different organizations for the reduction in blood borne infections, and increasing prevalence of cardiovascular diseases.

Read More :- https://www.marketsandmarkets.com/PressReleases/needles.asp

The key players in the global needles market are Hamilton Company (U.S.), Medtronic plc (Ireland), Becton, Dickinson and Company (U.S.), Stryker Corporation (U.S.), B. Braun Melsungen AG (Germany), Boston Scientific Corporation (U.S.), Terumo Corporation (Japan), Novo Nordisk A/s (Denmark), Smiths Medical (U.K.), and Thermo Fisher Scientific (U.S.).

Mycoplasma Testing Market : Geographical Snapshot of the Market

Factors driving the growth of this market are the rapid growth in the pharmaceutical and biotechnology industries, R&D investments and government support. Mycoplasma testing is carried out in the research and production of all biopharmaceutical products. Growth in the pharmaceutical and biotechnology sector across the globe serves as a direct driver for associated markets such as mycoplasma testing.

The Mycoplasma Testing Market is expected to reach USD 943.4 Million by 2022 from USD 523.3 Million in 2017, at a CAGR of 12.5%.

Download PDF Brochure :- 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=136509856

On the basis of products, the mycoplasma testing market is segmented into kits & reagents, instruments, and services. The kits & reagents segment is expected to dominate the global mycoplasma testing market in 2017. The frequent purchase of these consumables as compared to instruments and increasing use of kit-based techniques are key factors driving the growth of this segment.

Based on technique, the mycoplasma testing market is segmented into PCR, ELISA, direct assays, indirect assays, DNA staining, microbial culture techniques, and enzymatic methods. In 2017, the PCR technique segment is expected to account for the largest share of the mycoplasma testing market, by technique. The high acceptance rate of PCR due to the accuracy, speed, and flexibility provided by this technique in life sciences research is one of the major factors driving this segment.

Based on region, the mycoplasma testing market is segmented into North America, Europe, Asia, and Rest of the World (RoW). North America is expected to dominate the mycoplasma testing market in 2017 on account of the high adoption rate of novel technologies and a large number of life science research studies conducted in this region.

Read more :- https://www.marketsandmarkets.com/PressReleases/mycoplasma-testing.asp

Key players in the mycoplasma testing market include Thermo Fisher Scientific Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), SGS S.A. (Switzerland), American Type Culture Collection (U.S.) and  Bionique Testing Laboratories, Inc. (U.S.).

Research details developments in the Healthcare EDI Market

The rising adoption of EDI services by hospitals in supply chain management and government efforts to improve healthcare coverage & streamline healthcare delivery & reimbursement processes are majorly contributing to the growth of the European healthcare EDI market, which holds the second-largest market share.

The Healthcare EDI Market is expected to reach USD 3.77 Billion by 2022 from an estimated USD 2.56 Billion in 2017, at a CAGR of 8.1%. The growth of the market is mainly driven by the rising need to curtail healthcare costs, mandatory regulations for transaction processes, and government support for HCIT.

Download PDF Brochure :- 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=130571438

On the basis of component, the services segment accounted for the largest share of the global healthcare EDI market. This is primarily attributed to the increasing complexity and scale of EDI solutions, as they require extensive training programs, and rise in outsourcing activities. The services segment is also expected to grow at the highest CAGR during the forecast period.

Based on delivery mode, the web & cloud-based EDI segment accounted for the largest share of this market. The low cost of web and cloud-based EDI, non-requirement of software installations, compatibility with mobile devices, and high scalability are the major factors driving the use of web & cloud-based EDI, which has boosted the demand for effective EDI implementation.

North America accounted for the largest share of the healthcare EDI market in 2016, followed by Europe and Asia-Pacific. 

Read More :- https://www.marketsandmarkets.com/PressReleases/healthcare-edi.asp

The prominent players in the global healthcare EDI market are McKesson Corporation (U.S.), GE Healthcare (U.S.), Allscripts Healthcare Solutions Inc. (U.S.), Cognizant Technology Corporation (U.S.), SSI Group, LLC (U.S.), Cerner Corporation (U.S.), Comarch SA (Poland), Axway Software SA (France), Optum Inc. (U.S.), Dell Technologies Inc. (U.S.), Quality Systems Inc. (U.S.), and Synnex Corporation (U.S.).

Vascular Stents Market : Emerging Trends and Global Forecast

The growth of this market is majorly driven by the technological advancements in stents, increasing number of angioplasty procedures, rising burden of vascular diseases, increasing demand for minimally invasive procedures, and rising geriatric population. However, the presence of alternative treatment methods for vascular diseases, stringent regulations for product approval, and numerous cases of product failure and product recalls are expected to restrain the growth of the vascular stents market during the forecast period of 2016 to 2021.

The global Vascular Stent Market is projected to reach USD 17.68 billion by 2021 from USD 12.21 billion in 2016, at a CAGR of 7.7% during the forecast period.

Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=199869009

This report segments the vascular stents market based on product, type, mode of delivery, material, end user, and region. 

Based on type, the market is segmented into bare-metal stents, drug-eluting stents, and bioabsorbable stents. The drug-eluting stents segment is expected to account for the largest share of the vascular stents market in 2016. This can primarily be attributed to the advantages of drug-eluting stents over bare-metal stents, such as lower risk of restenosis and other related complications.  

Based on the mode of delivery, the vascular stents market is segmented into balloon-expandable stents and self-expanding stents. The balloon-expandable stents segment is expected to grow at the highest CAGR during the forecast period primarily due to the growing regulatory approvals for balloon-expandable stents and the high usage of these stents in angioplasty procedures.

Based on region, the vascular stents market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America was the largest market for vascular stents in 2016. However, the Asian market is projected to register the highest growth during the forecast period. 

Read more :- https://www.marketsandmarkets.com/PressReleases/vascular-stent.asp

The key players operating in this market include Medtronic, plc (Ireland), Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.), BIOTRONIK SE & Co. KG (Germany), B. Braun Melsungen AG (Germany), Terumo Corporation (Japan), STENTYS SA (France), MicroPort Scientific Corporation (China), Meril Life Sciences Pvt. Ltd. (India), Vascular Concepts (India), W. L. Gore and Associates (U.S.), C. R. Bard (U.S.), Endologix, Inc. (U.S.), Lombard Medical Technologies (U.K.), Translumina GmbH (Germany), and JOTEC GmbH (Germany).

Pharmaceutical Packaging Equipment Market - Global Forecast to 2023

The major factors driving the growth of this market largely driven by the growth in the generic and biopharmaceutical markets, the growing need for flexible and integrated packaging equipment, the increase in offshore pharmaceutical manufacturing, growing contract manufacturing of pharmaceutical products, and the introduction of regulatory standards on packaging & stringent norms against counterfeit products. Moreover, the pharmaceutical industry is witnessing a shift toward the use of biopharmaceuticals and biological drugs. This has led to an increased demand for innovative packages.

The Pharmaceutical Packaging Equipment Market is expected to reach USD 8.9 billion by 2023 from an estimated USD 6.2 billion in 2018, at a CAGR of 7.4%. 

Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=19845828

Based on product, the market is divided into primary packaging equipment, secondary packaging equipment, and labeling and serialization equipment. The primary packaging equipment segment accounted for the largest share in the pharmacetuical packaging equipment market. The ease of handling and shelving of pharmaceuticals after primary packaging, development of novel forms of drug delivery and biopharmaceuticals (stimulating the need for innovation in primary packaging), and the increasing number of regulatory norms and quality control criteria have contributed to the largest share of primary packaging equipment in pharmaceutical packaging equipment market.

Based on type, the pharmaceutical packaging equipment market is segmented into liquid, solid, semi-solid, and other packaging equipment. The liquid packaging equipment segment is expected to account for the largest share of the global pharmaceutical packaging equipment market during the forecast period of 2018 to 2023. The large share of this segment can be attributed to the transition toward new biopharmaceutical compounds (leading to the production of increasingly complex formulations), rising incidence of eye disorders, and development of novel drug delivery systems have increased the demand for novel packaging, such as automated and integrated packaging lines. In addition, the demand for specialized packaging equipment.

Europe is expected to account for the largest share of the pharmaceutical packaging equipment market in 2018, followed by North America and the Asia Pacific. The presence of a large number of pharmaceutical packaging equipment manufacturing companies, growing generics market, and rising geriatric population (and the subsequent increase in the prevalence of chronic diseases).

Read more :- https://www.marketsandmarkets.com/PressReleases/pharmaceutical-packaging-equipment.asp

The prominent players in the pharmaceutical packaging equipment market are Robert Bosch (Germany), IMA (Italy), Marchesini Group (Italy), Körber (Germany), MG2 (Italy), Uhlmann Group (Germany), Accutek Packaging Equipment Companies (US), Vanguard Pharmaceuticals Machinery (US), Romaco Holding (Germany), Bausch + Ströbel (Germany), OPTIMA Packaging Group (Germany), ACG Worldwide (India), Coesia (Italy), and MULTIVAC Group (Germany).

Insulin Delivery Devices Market : An Outlook to the Future Global Opportunities

The growth of the market is attributed favorable reimbursement scenario and strong government support in selected countries, technological advancements in insulin delivery devices, and growing diabetic population. Increasing research and development activities and increase in diabetes-related health expenditure in emerging economies are expected to offer significant growth opportunities for manufacturers in the coming years.

The Insulin Delivery Devices Market is expected to reach USD 17.8 billion by 2021 from USD 11.5 billion in 2016, at a CAGR of 9.1% during the forecast period. 

Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107632092

Based on type, the insulin delivery devices market is categorized into pens, pumps, pen needles, syringes, and others (insulin inhalers, transdermal patches, and insulin jet injectors, among others). In 2016, the pens segment is expected to command the largest share of the insulin delivery devices market. The pens segment is further divided into reusable and disposable pens. The reusable pens segment is estimated to command the largest share of the insulin pens market in 2016. This large share can be attributed to lower price compared to disposable pens; availability of reimbursement in selected countries, and increasing adoption of insulin pens in the Asia-Pacific region.

By end user, the insulin delivery devices market is segmented into patients/homecare and hospitals & clinics.  The patients/homecare segment is estimated to command the largest share of the market in 2016 and is expected to grow at the highest CAGR during the forecast period. Growth in this segment can be primarily attributed to the increasing diabetic population and rising healthcare expenditure.

In 2016, North America is expected to account for the largest share of the global insulin delivery devices market. North America’s leadership position in the market can be attributed to the rising prevalence of diabetes and favorable reimbursement scenarios in the US and Canada, awareness activities, venture capital investments and issuance of IPOs in the US, and regulations for the usage of safety-engineered needles in Canada.

Read more :- https://www.marketsandmarkets.com/PressReleases/insulin-delivery-device.asp

The insulin delivery devices market is highly competitive with the presence of several small and big players. Some of the players in the insulin delivery devices market include Becton, Dickinson and Company (US), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), Medtronic plc (Ireland), Animas Corporation (US), Tandem Diabetes Care, Inc. (US), Sanofi (France), Biocon Ltd. (India), Eli Lilly and Company (US), and Insulet Corporation (US).

Veterinary Imaging Market - Global Forecast to 2022

The growth of the market during the forecast period is mainly driven by the increase in animal healthcare spending, growing pet insurance purchase, the growing companion animals market, increase in the number of veterinary practitioners and their income levels in developed regions, and launch of portable battery charge imaging instruments. However, the high cost of veterinary imaging instruments and increasing pet care expenditure are expected to restrain the overall market growth, to a certain extent, during the forecast period.

The Veterinary Imaging Market is expected to reach USD 1.94 Billion by 2022 from an estimated USD 1.40 Billion in 2017, at a CAGR of 6.8%. 

Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=80889726

In this report, the global veterinary imaging market is segmented by product, therapeutic area, animal, end user, and region. 

On the basis of product, the global veterinary imaging market is segmented into instruments, reagents, and software. The veterinary imaging instruments segment includes radiography systems, ultrasound imaging systems, magnetic resonance imaging (MRI) systems, computed tomography (CT) imaging systems, video endoscopy imaging systems, and other imaging systems (including thermal imaging systems and optical coherent tomography). The radiography systems segment accounted for the largest share of the global veterinary imaging instruments market in 2016. 

On the basis of therapeutic area, the global veterinary imaging market is segmented into orthopedics & traumatology, oncology, cardiology, neurology, and other therapeutic areas. The orthopedics & traumatology segment accounted for the largest share of the global veterinary imaging market in 2016. The large share of this segment can be attributed to the increasing incidence of bone injuries and rising prevalence of arthritis and lameness disease in animals. 

Based on animal type, the global veterinary imaging market is segmented into small companion animals, large animals, and other animals. The small companion animals segment accounted for the largest share of the market in 2016. 

The global veterinary imaging market, by end user, is segmented into clinics and hospitals & academic institutions. Clinics are the major end users in the veterinary imaging market and accounted for a share in 2016. 

North America represented the largest veterinary imaging market in 2016, followed by Europe and Asia-Pacific. The Asia-Pacific market is expected to register the highest CAGR during the forecast period. 

Read more :- https://www.marketsandmarkets.com/PressReleases/veterinary-imaging.asp

The major players in the global veterinary imaging market are GE Healthcare (U.S.), Agfa- Gevaert N.V. (Belgium), Excelsior Union Limited (Russia), Onex Corporation (Canada), Esaote S.p.A (Italy), Canon Inc. (Japan), IDEXX Laboratories, Inc. (U.S.), VCA Inc. (U.S.), Hitachi, Ltd (Japan), BCF Technology, Ltd. (U.K.), Siemens AG (Germany), Diagnostic Imaging Systems, Inc. (U.S.), Hallmarq Veterinary Imaging Ltd. (U.K.), MinXray, Inc. (U.S.), and Fujifilm Holdings Corporation (Japan).

Pharmaceutical Filtration Market to witness major growth in coming years

The report Pharmaceutical Filtration Market provides a detailed overview of major drivers, restraints, challenges, opportunities, current market trends and strategies impacting the global market along with estimates and forecast of revenue.

Market growth is primarily driven by factors such as growing production of large molecules and biologics, technological advancements in nanofibers, growth in the generics market, and regulatory mandates for cleanrooms in pharmaceutical production. Other factors supporting market growth include an increase in R&D spending by biopharmaceutical companies to offer a strong biologics pipeline.         

The global Pharmaceutical Filtration Market is poised to reach USD 22.71 Billion by 2021 from USD 13.73 Billion in 2016, at a CAGR of 10.6% from 2016 to 2021.

Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209343847

The global pharmaceutical filtration market is segmented on the basis of product, technique, application, scale of operation, and region. 

On the basis of product, the pharmaceutical filtration market is segmented into membrane filters, prefilters and depth media filters, cartridge & capsule filters, single-use systems, filter holders, filtration accessories, and other products. In 2016, the membrane filters segment accounted for the largest share of the market. This segment is also expected to register the highest CAGR during the forecast period. 

Based on application, the final product-processing segment is expected to register the highest CAGR during the forecast period owing to the rapidly growing biologics and generic drug production coupled with the presence of stringent regulatory guidelines to maintain a clean and safe manufacturing environment.

North America accounted for the largest share of the global pharmaceutical filtration market in 2016, followed by Europe. Stringent regulatory guidelines to provide safe drugs is encouraging the use of pharmaceutical filtration products and the presence of a large number of market players are propelling the growth of the North American pharmaceutical filtration market. The Asian region is expected to register the highest CAGR in the forecast period. 

Read More :- https://www.marketsandmarkets.com/PressReleases/pharmaceutical-filtration.asp

The pharmaceutical filtration market is dominated by established players such as Merck KGaA (Germany), GE Healthcare (U.S.), Pall Corporation (U.S.), Parker Hannifin Corporation (U.S.), and Sartorius Stedim Biotech S.A. (France).

Stem Cell Therapy Market to witness major growth in coming years

Factors such as the growing awareness related to the therapeutic potency of stem cells in disease management, development of advanced genome-based cell analysis techniques, increasing public-private investments for stem cell research, identification of new stem cell lines, and developments in infrastructure for stem cell banking and processing are propelling the growth of the global stem cell therapy market.

The report studies the Stem Cell Therapy Market market during the forecast period of 2016 to 2022. The market is expected to reach USD 161.8 million by 2022, growing at a CAGR of 11.0% during the forecast period. 

Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48

On the basis of mode of therapy, the global stem cell therapy market is divided into two major categories, namely, allogeneic stem cell therapy and autologous stem cell therapy. The allogeneic stem cell therapy segment is expected to command the largest share of 95.2% in the global stem cell therapy market in 2017 growing at a CAGR of 11.2% during the forecast period. This large share can primarily be attributed to the rising commercialization of allogeneic stem cell therapy products, wider therapeutic applications of allogeneic stem cells, easy production scale-up process, and growing number of clinical trials related to allogeneic stem cell therapies.

On the basis of therapeutic application, the global stem cell therapy market is segmented into musculoskeletal disorders, wounds and injuries, cardiovascular diseases, surgeries, gastrointestinal diseases, and other applications. The musculoskeletal disorders segment is expected to command the largest share of 61.1% in the global stem cell therapy market in 2017. Furthermore, the CVS diseases segment is expected to grow at the highest CAGR of 13.0% during the forecast period. 

On the basis of cell source, the global stem cell therapy market is divided into adipose derived MSCs, bone marrow derived MSCs, embryonic / cord blood SCs, and other cell sources. The adipose derived MSCs segment was expected to account for the largest share of 59.1% in the global stem cell therapy market in 2017. Furthermore, the bone marrow derived MSCs segment is expected to grow at highest CAGR of 12.1% during the forecast period.

North America is expected to be the largest regional segment in the global stem cell therapy market in 2017, followed by Asia-Pacific. In addition, the North American stem cell therapy market is expected to be the fastest growing region during the forecast period, growing at a CAGR of 11.5%. 

Read More :- https://www.marketsandmarkets.com/PressReleases/stem-cells-market.asp

As of 2016, Osiris Therapeutics, Inc. (U.S.), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l. (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (U.S.), RTI Surgical, Inc. (U.S.), and AlloSource (U.S.) were some of the key players operating in the global stem cell therapy market

Hemodialysis & Peritoneal Dialysis Market statistics and research analysis released in latest report

Growth in this market is driven by the increasing number of ESRD patients, growing prevalence of diabetes & hypertension, shortage of organ donors and risks associated with transplant, technological advancements and new product launches, and rising R&D expenditure for developing new dialysis products.

The report "Hemodialysis & Peritoneal Dialysis Market is projected to reach USD 99.2 billion by 2024 from USD 74.2 billion in 2019, at a CAGR of 6.0%

Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1279

The global hemodialysis market is broadly categorized into two segments, namely, hemodialysis products and hemodialysis services market. The hemodialysis products market include machines (center-use & home-use machines) & consumables (dialyzers, access products, bloodlines, dialysates, and other consumables). The hemodialysis services (including in-center & home- hemodialysis services) segment is expected to account for the largest share of the hemodialysis market. 

The peritoneal dialysis market, by modality, includes continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD). The APD segment is expected to grow at the highest CAGR owing to its several advantages over CAPD, such as daytime freedom for patients, fewer connections and disconnections (and hence a lower probability of peritonitis), and improved quality of life. Being automated, APD is also the preferred dialysis treatment for the elderly and children.

Based on region, the hemodialysis and peritoneal dialysis market has been segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to account for the largest share of the hemodialysis and peritoneal dialysis market in 2019. The higher per capita income as compared to other regions, favorable reimbursement scenario, and increasing demand for dialysis procedures are propelling the growth of the market.

Read More :- https://www.marketsandmarkets.com/PressReleases/dialysis.asp

The major players operating in the global hemodialysis and peritoneal dialysis market are Fresenius Medical Care AG & Co. KGaA (Germany), DaVita Healthcare Partners, Inc. (US), Baxter International, Inc. (US), and B. Braun Melsungen AG (Germany). Other players in this market include Ion Nipro Corporation (Japan), Cantel Medical Corporation (US), NIKKISO CO., LTD (Japan), Diaverum Healthcare Partners (Germany), Asahi Kasei Corporation (Japan), Medtronic Plc (Ireland), Rockwell Medical, Inc. (US), Becton, Dickinson and Company (US), Dialife Group (Switzerland), and Isopure Corp. (US), among others.

High-performance Liquid Chromatography (HPLC) Market - Global Forecast to 2025

The growth in this market is driven byhigh sensitivity &accuracy of the HPLC technique, the growing importance of HPLC tests in drug approvals,the rising popularity of hyphenated techniques, and increasing pharmaceutical R&D spending. However, the high cost of HPLC systems is expected to restrict market growth to a certain extent.

The report High-performance Liquid Chromatography (HPLC) Market , is projected to reach USD 5.7billion by 2025 from USD 4.5billion in 2020, at a CAGR of 4.6% during the forecast period. 

Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=117899209

Based on the product, the market was divided into instruments, consumables, and accessories. The instrument market is subjected to account for the largest share in the HPLC market and consumables to growth at the highest rate during the forecast period. The need to analyze compounds in trace concentration and the extensive use of the system in forensic institutes and industries such as pharmaceuticals, food, nutraceuticals, cosmetics, and environmental testing calls for growth of the segment.

Based onthe application, the HPLC market is divided into clinical research, diagnostics, forensics, and other applications. Clinical research is subjected to grow at the highest rate in the forecast period. A rise in pharmaceutical and biotechnological research fueled by the need for numerous preclinical and clinical studies performed during the drug discovery and development processis said to drive the market.

North America is expected to account for the largest share of the global HPLC market. Market growth in this region is driven primarily by the increase in R&D funding, the growing number of preclinical activities by CROs &pharmaceutical companies, and the increasing food & agricultural industry in Canada. 

Read More :- https://www.marketsandmarkets.com/PressReleases/hplc.asp

The global HPLC market is well established owing to the dominance of prominent market players, such as Waters (US), Agilent (US), Shimadzu (Japan), Thermo Fisher (US), PerkinElmer (US), GE Healthcare (US), Bio-Rad (US), Merck Millipore (Germany), Hitachi (Japan), Showa Denko (Japan), Gilson (US), Phenomenex (US), JASCO (US), Hamilton Company (US), SIELC (US), Orochem (US), YMC Co. Ltd. (Japan), Restek (US), Trajan Scientific (Australia), and Tosoh Bioscience LLC (Japan).

Cholesterol Testing Services Market to Witness Steady Growth in the Near Future

Factors such as increasing incidence of cardiovascular diseases and obesity, physician preference of laboratory testing rather self-testing, growing awareness and adoption of preventive healthcare, government initiatives to improve the quality of testing, and rapid growth in the geriatric population are propelling the growth of this market. Moreover, emerging economies offer significant growth opportunities for players operating in the cholesterol testing services market. 

The global Cholesterol Testing Services Market is expected to reach USD 17.57 Billion by 2021 from an estimated value of USD 11.96 Billion in 2016, growing at a CAGR of 8% during the forecast period.

Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180941049

The cholesterol testing services market is segmented on the basis of type of customer and region. Based on type of customer, the market is segmented into physicians/providers and hospitals; employers, health plans, and Managed Care Organizations (MCOs); government agencies, Accountable Care Organizations (ACOs), and Integrated Delivery Networks (IDNs); and patients. 

The patient-driven cholesterol testing segment is expected to grow at the highest CAGR during the forecast period, mainly due to increasing awareness and adoption of preventive healthcare, availability of lab test services for patients without any physician intervention thus reducing the waiting time to get appointment from physicians, and online access to reports and readings through smartphones.

Based on region, the cholesterol testing services market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). In 2016, North America is expected to dominate the market, followed by Europe. However, the cholesterol testing services market in the Asian region is expected to witness the highest CAGR during the forecast period mainly due to large population in the region, increased prevalence of cardiovascular diseases, increasing awareness in masses for preventive healthcare, and large number of testing facilities available in the Asian region.

Read More :- https://www.marketsandmarkets.com/PressReleases/cholesterol-testing-services.asp

Prominent players in the market include Laboratory Corporation of America Holdings (LabCorp) (U.S.), Quest Diagnostics Incorporated (U.S.), Eurofins Scientific (Luxembourg), Spectra Laboratories Inc. (U.S.), Unilabs (Switzerland), SYNLAB International GmbH (Germany), Bio-Reference Laboratories Inc. (U.S.), Clinical Reference Laboratory, Inc. (CRL) (U.S.), ACM Medical Laboratory (U.S.), and Adicon Clinical Laboratory (China).

Pharmaceutical Membrane Filtration Market worth $8.6 billion by 2024 explored in latest research

The growth of this market is primarily driven by the growth of the pharmaceutical and biopharmaceutical industry, increasing demand for single-use technologies, and the advancements in nanofiltration techniques.

The global Pharmaceutical Membrane Filtration Market is valued at an estimated USD 5.1 billion in 2019 and is projected to reach USD 8.6 billion by 2024, growing at a CAGR of 11.0% during the forecast period.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=255408031

On the basis of product, the pharmaceutical membrane filtration market is segmented into filters, systems, and accessories. Filters formed the largest product segment in this market owing to the high and growing use of different types of membrane filters for various filtration applications in the biopharmaceutical manufacturing industry.

On the basis of application, the pharmaceutical membrane filtration market is segmented into final product processing, raw material filtration, cell separation, water purification, and air purification. Final product processing was the largest application segment in the pharmaceutical membrane filtration market in 2018. 

The global pharmaceutical membrane filtration market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America was the largest market for pharmaceutical membrane filtration, followed by Europe. The large share of North America can be attributed to several factors, such as the presence of key biopharmaceutical manufacturing facilities in the region and the significant spending on research and development activities in the US.

Read More :- https://www.marketsandmarkets.com/PressReleases/pharmaceutical-membrane-filtration.asp

The major companies operating in the pharmaceutical membrane filtration market include Merck Millipore (Germany), Danaher (US) and Sartorius Stedim Biotech (France).

Top 10 Cellular Analysis Market outlook with industry review and forecasts

The major factors driving the growth of this market are the growing biotechnology and biopharmaceutical industries, introduction of technologically advanced cell analysis instruments, increasing incidence of infectious and chronic diseases and rising number of patients suffering from cancer, and increasing investments from various government associations & life sciences companies for cell biology research activities.

The Top 10 Cellular Analysis Market is expected to reach USD 41.34 Billion by 2021 from USD 28.66 Billion in 2016, at a CAGR of 7.6% from 2016 to 2021. 

This report segments the top 10 cellular analysis market on the basis of technology, application, end user, and region. 

Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=247924081

Based on technology, the top 10 cellular analysis market is segmented into cell imaging techniques, polymerase chain reaction (PCR), flow cytometry, cell counting, spectrophotometry, blotting, high-content screening, cell microarray, sample preparation technologies, and centrifugation. 

The cell imaging techniques segment is expected to dominate the top 10 cellular analysis market in 2016. The increasing number of cancer cases, rising investments in cell biology research, and introduction of technologically advanced cell imaging instruments for the morphological & anatomical examination of specific or group of cells are factors contributing to the growth of this segment.

On the basis of application, the top 10 cellular analysis market is segmented into biopharmaceutical applications, stem cell research, cancer research, instruments, tissue engineering & regenerative medicine, and other applications (in vitro diagnostics, organ cultures, virology, IVF, and genetic counselling). 

On the basis of end user, the top 10 cellular analysis market is segmented into hospitals and diagnostic laboratories, cell banks, research laboratories and institutes, biotechnology and pharmaceutical companies, and other end users. 

Read More :- https://www.marketsandmarkets.com/PressReleases/top-10-cellular-analysis.asp

On the basis of region, the top 10 cellular analysis market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share of the market in 2016. 

Key players in the top 10 cellular analysis market include Bio-Rad Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies (U.S.), Beckman Coulter, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), GE Healthcare (U.S.), Olympus Corporation (Japan), Tecan Group (Switzerland), and Nikon Instruments (Japan).